Smokers with cardiovascular disease enrolled in a cessation trial identified health concerns, financial implications, and behavioral strategies as key facilitators, which were weighed against barriers including addiction, difficult life situations, and lack of support from health professionals.
In patients with atherosclerotic cardiovascular disease, smoking cessation is influenced by a complex interplay of individual and contextual factors, highlighting the potential value of tailored motivational interviewing and peer support groups.
Objectives: Smoking is common in patients with cardiovascular disease. Despite strong recommendations for cessation and the existence of efficacious pharmacological and behavioral interventions, cessation rates remain low. Therefore, in this study, we explore perceived facilitators and barriers to smoking cessation in patients with atherosclerotic cardiovascular disease who have participated in a cessation intervention study. Methods: = 10) from the intervention arm of a randomized controlled study with access to free cessation support and pharmacological aids completed a semi-structured, in-depth telephone interview after a 6-monthfollow-up between October 2021 and July 2022. The interviews were audio recorded, transcribed, and analyzed according to principles of thematic analysis. Results: The mean age was 65.7 (range: 55-79) years, and three of the 10 participants were women. Among the participants, five had quit smoking, three had relapsed, and two were persistent smokers. The themes identified encompassed barriers and facilitators to cessation, both including individual and contextual factors. Barriers included the upsides of smoking, difficult life situations, addiction to smoking, smoking in social circles, perceived lack of support and understanding from health professionals. Facilitators included intrinsic motivation, concerns about the health condition, financial implications, specific behavioral strategies, positive influence from the social environment, and helpful components of the cessation intervention. Conclusion: Smokers with cardiovascular disease who have attended a cessation intervention study report several facilitators weighted against barriers, interacting with the intention to cease smoking. The most important potentially modifiable factors of significance for cessation identified may be addressed through motivational interviews and focus groups with other smokers.
Getz et al. (Wed,) conducted a other in Atherosclerotic cardiovascular disease and chronic smoking (n=10). Smoking cessation intervention (motivational interviewing, pharmacological aids, and behavioral support) was evaluated on Perceived facilitators and barriers to smoking cessation. Smokers with cardiovascular disease enrolled in a cessation trial identified health concerns, financial implications, and behavioral strategies as key facilitators, which were weighed against barriers including addiction, difficult life situations, and lack of support from health professionals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: